Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Zalasta 10mg orodispersible tablets
040201060BCAHAT
|
Zalasta | Olanzapine | Central Nervous System | 2 |
|
Zalasta 5mg tablets
040201060BCABAA
|
Zalasta | Olanzapine | Central Nervous System | 2 |
|
Zalasta 10mg tablets
040201060BCADAC
|
Zalasta | Olanzapine | Central Nervous System | 1 |
|
Zalasta 15mg orodispersible tablets
040201060BCAIAU
|
Zalasta | Olanzapine | Central Nervous System | No data available |
|
Zalasta 15mg tablets
040201060BCAEAL
|
Zalasta | Olanzapine | Central Nervous System | No data available |
|
Zalasta 2.5mg tablets
040201060BCAAAD
|
Zalasta | Olanzapine | Central Nervous System | No data available |
|
Zalasta 20mg orodispersible tablets
040201060BCAJAV
|
Zalasta | Olanzapine | Central Nervous System | No data available |
|
Zalasta 20mg tablets
040201060BCAFAQ
|
Zalasta | Olanzapine | Central Nervous System | No data available |
|
Zalasta 5mg orodispersible tablets
040201060BCAGAS
|
Zalasta | Olanzapine | Central Nervous System | No data available |
|
Zalasta 7.5mg tablets
040201060BCACAB
|
Zalasta | Olanzapine | Central Nervous System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.